Ranibizumab (Lucentis) — Competitive Intelligence Brief

Ranibizumab (Lucentis) (Ranibizumab (Lucentis)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF-A inhibitor (monoclonal antibody fragment). Area: Ophthalmology.

marketed VEGF-A inhibitor (monoclonal antibody fragment) VEGF-A (Vascular Endothelial Growth Factor A) Ophthalmology Small molecule

Target snapshot

Ranibizumab (Lucentis) (Ranibizumab (Lucentis)) — Greater Houston Retina Research. Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ranibizumab (Lucentis) TARGET	Ranibizumab (Lucentis)	Greater Houston Retina Research	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Intravitreal ranibizumab	Intravitreal ranibizumab	LEANDRO CABRAL ZACHARIAS	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Lucentis every 4 weeks	Lucentis every 4 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
Lucentis every 12 weeks	Lucentis every 12 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
intra-vitreal injection of Ranibizumab	intra-vitreal injection of Ranibizumab	Ain Shams University	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Lucentis (ranibizumab)	Lucentis (ranibizumab)	Samsung Bioepis Co., Ltd.	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Ranibizumab Control	Ranibizumab Control	AbbVie	phase 3	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF-A inhibitor (monoclonal antibody fragment) class)

1. Retinal Consultants of Arizona · 2 drugs in this class
2. Ain Shams University · 1 drug in this class
3. Greater Houston Retina Research · 1 drug in this class
4. Hoffmann-La Roche · 1 drug in this class
5. LEANDRO CABRAL ZACHARIAS · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. AbbVie · 1 drug in this class
8. Samsung Bioepis Co., Ltd. · 1 drug in this class